Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Ai Oncology Analytical Solution Market

ID: MRFR/Pharma/29356-HCR
128 Pages
Rahul Gotadki
Last Updated: April 24, 2026

AI in Oncology for Analytical Solution Market Research Report: Size, Share, Trend Analysis By Types (Software, Services), By Solution (Clinical Decision Support, Drug Discovery and Development, Medical Imaging Analysis, Personalized Medicine), By End-User (Hospitals and Clinics, Research institutions, Pharmaceutical Companies, Diagnostic Laboratories), By Cancer Type (Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Melanoma) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Ai Oncology Analytical Solution Market Infographic
Purchase Options
Compare License
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Type (USD Billion)
  49.     4.1.1 Software
  50.     4.1.2 Services
  51.   4.2 Healthcare, BY Solution (USD Billion)
  52.     4.2.1 Clinical Decision Support
  53.     4.2.2 Drug Discovery and Development
  54.     4.2.3 Medical Imaging Analysis
  55.     4.2.4 Personalized Medicine
  56.   4.3 Healthcare, BY End-User (USD Billion)
  57.     4.3.1 Hospitals and Clinics
  58.     4.3.2 Research Institutions
  59.     4.3.3 Pharmaceutical Companies
  60.     4.3.4 Diagnostic Laboratories
  61.   4.4 Healthcare, BY Cancer Type (USD Billion)
  62.     4.4.1 Lung Cancer
  63.     4.4.2 Breast Cancer
  64.     4.4.3 Prostate Cancer
  65.     4.4.4 Colorectal Cancer
  66.     4.4.5 Melanoma
  67.   4.5 Healthcare, BY Region (USD Billion)
  68.     4.5.1 North America
  69.       4.5.1.1 US
  70.       4.5.1.2 Canada
  71.     4.5.2 Europe
  72.       4.5.2.1 Germany
  73.       4.5.2.2 UK
  74.       4.5.2.3 France
  75.       4.5.2.4 Russia
  76.       4.5.2.5 Italy
  77.       4.5.2.6 Spain
  78.       4.5.2.7 Rest of Europe
  79.     4.5.3 APAC
  80.       4.5.3.1 China
  81.       4.5.3.2 India
  82.       4.5.3.3 Japan
  83.       4.5.3.4 South Korea
  84.       4.5.3.5 Malaysia
  85.       4.5.3.6 Thailand
  86.       4.5.3.7 Indonesia
  87.       4.5.3.8 Rest of APAC
  88.     4.5.4 South America
  89.       4.5.4.1 Brazil
  90.       4.5.4.2 Mexico
  91.       4.5.4.3 Argentina
  92.       4.5.4.4 Rest of South America
  93.     4.5.5 MEA
  94.       4.5.5.1 GCC Countries
  95.       4.5.5.2 South Africa
  96.       4.5.5.3 Rest of MEA
  97. 5 SECTION V: COMPETITIVE ANALYSIS
  98.   5.1 Competitive Landscape
  99.     5.1.1 Overview
  100.     5.1.2 Competitive Analysis
  101.     5.1.3 Market share Analysis
  102.     5.1.4 Major Growth Strategy in the Healthcare
  103.     5.1.5 Competitive Benchmarking
  104.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  105.     5.1.7 Key developments and growth strategies
  106.       5.1.7.1 New Product Launch/Service Deployment
  107.       5.1.7.2 Merger & Acquisitions
  108.       5.1.7.3 Joint Ventures
  109.     5.1.8 Major Players Financial Matrix
  110.       5.1.8.1 Sales and Operating Income
  111.       5.1.8.2 Major Players R&D Expenditure. 2023
  112.   5.2 Company Profiles
  113.     5.2.1 IBM (US)
  114.       5.2.1.1 Financial Overview
  115.       5.2.1.2 Products Offered
  116.       5.2.1.3 Key Developments
  117.       5.2.1.4 SWOT Analysis
  118.       5.2.1.5 Key Strategies
  119.     5.2.2 Siemens Healthineers (DE)
  120.       5.2.2.1 Financial Overview
  121.       5.2.2.2 Products Offered
  122.       5.2.2.3 Key Developments
  123.       5.2.2.4 SWOT Analysis
  124.       5.2.2.5 Key Strategies
  125.     5.2.3 Philips (NL)
  126.       5.2.3.1 Financial Overview
  127.       5.2.3.2 Products Offered
  128.       5.2.3.3 Key Developments
  129.       5.2.3.4 SWOT Analysis
  130.       5.2.3.5 Key Strategies
  131.     5.2.4 GE Healthcare (US)
  132.       5.2.4.1 Financial Overview
  133.       5.2.4.2 Products Offered
  134.       5.2.4.3 Key Developments
  135.       5.2.4.4 SWOT Analysis
  136.       5.2.4.5 Key Strategies
  137.     5.2.5 CureMetrix (US)
  138.       5.2.5.1 Financial Overview
  139.       5.2.5.2 Products Offered
  140.       5.2.5.3 Key Developments
  141.       5.2.5.4 SWOT Analysis
  142.       5.2.5.5 Key Strategies
  143.     5.2.6 Tempus (US)
  144.       5.2.6.1 Financial Overview
  145.       5.2.6.2 Products Offered
  146.       5.2.6.3 Key Developments
  147.       5.2.6.4 SWOT Analysis
  148.       5.2.6.5 Key Strategies
  149.     5.2.7 PathAI (US)
  150.       5.2.7.1 Financial Overview
  151.       5.2.7.2 Products Offered
  152.       5.2.7.3 Key Developments
  153.       5.2.7.4 SWOT Analysis
  154.       5.2.7.5 Key Strategies
  155.     5.2.8 Freenome (US)
  156.       5.2.8.1 Financial Overview
  157.       5.2.8.2 Products Offered
  158.       5.2.8.3 Key Developments
  159.       5.2.8.4 SWOT Analysis
  160.       5.2.8.5 Key Strategies
  161.     5.2.9 Zebra Medical Vision (IL)
  162.       5.2.9.1 Financial Overview
  163.       5.2.9.2 Products Offered
  164.       5.2.9.3 Key Developments
  165.       5.2.9.4 SWOT Analysis
  166.       5.2.9.5 Key Strategies
  167.   5.3 Appendix
  168.     5.3.1 References
  169.     5.3.2 Related Reports
  170. 6 LIST OF FIGURES
  171.   6.1 MARKET SYNOPSIS
  172.   6.2 NORTH AMERICA MARKET ANALYSIS
  173.   6.3 US MARKET ANALYSIS BY TYPE
  174.   6.4 US MARKET ANALYSIS BY SOLUTION
  175.   6.5 US MARKET ANALYSIS BY END-USER
  176.   6.6 US MARKET ANALYSIS BY CANCER TYPE
  177.   6.7 CANADA MARKET ANALYSIS BY TYPE
  178.   6.8 CANADA MARKET ANALYSIS BY SOLUTION
  179.   6.9 CANADA MARKET ANALYSIS BY END-USER
  180.   6.10 CANADA MARKET ANALYSIS BY CANCER TYPE
  181.   6.11 EUROPE MARKET ANALYSIS
  182.   6.12 GERMANY MARKET ANALYSIS BY TYPE
  183.   6.13 GERMANY MARKET ANALYSIS BY SOLUTION
  184.   6.14 GERMANY MARKET ANALYSIS BY END-USER
  185.   6.15 GERMANY MARKET ANALYSIS BY CANCER TYPE
  186.   6.16 UK MARKET ANALYSIS BY TYPE
  187.   6.17 UK MARKET ANALYSIS BY SOLUTION
  188.   6.18 UK MARKET ANALYSIS BY END-USER
  189.   6.19 UK MARKET ANALYSIS BY CANCER TYPE
  190.   6.20 FRANCE MARKET ANALYSIS BY TYPE
  191.   6.21 FRANCE MARKET ANALYSIS BY SOLUTION
  192.   6.22 FRANCE MARKET ANALYSIS BY END-USER
  193.   6.23 FRANCE MARKET ANALYSIS BY CANCER TYPE
  194.   6.24 RUSSIA MARKET ANALYSIS BY TYPE
  195.   6.25 RUSSIA MARKET ANALYSIS BY SOLUTION
  196.   6.26 RUSSIA MARKET ANALYSIS BY END-USER
  197.   6.27 RUSSIA MARKET ANALYSIS BY CANCER TYPE
  198.   6.28 ITALY MARKET ANALYSIS BY TYPE
  199.   6.29 ITALY MARKET ANALYSIS BY SOLUTION
  200.   6.30 ITALY MARKET ANALYSIS BY END-USER
  201.   6.31 ITALY MARKET ANALYSIS BY CANCER TYPE
  202.   6.32 SPAIN MARKET ANALYSIS BY TYPE
  203.   6.33 SPAIN MARKET ANALYSIS BY SOLUTION
  204.   6.34 SPAIN MARKET ANALYSIS BY END-USER
  205.   6.35 SPAIN MARKET ANALYSIS BY CANCER TYPE
  206.   6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE
  207.   6.37 REST OF EUROPE MARKET ANALYSIS BY SOLUTION
  208.   6.38 REST OF EUROPE MARKET ANALYSIS BY END-USER
  209.   6.39 REST OF EUROPE MARKET ANALYSIS BY CANCER TYPE
  210.   6.40 APAC MARKET ANALYSIS
  211.   6.41 CHINA MARKET ANALYSIS BY TYPE
  212.   6.42 CHINA MARKET ANALYSIS BY SOLUTION
  213.   6.43 CHINA MARKET ANALYSIS BY END-USER
  214.   6.44 CHINA MARKET ANALYSIS BY CANCER TYPE
  215.   6.45 INDIA MARKET ANALYSIS BY TYPE
  216.   6.46 INDIA MARKET ANALYSIS BY SOLUTION
  217.   6.47 INDIA MARKET ANALYSIS BY END-USER
  218.   6.48 INDIA MARKET ANALYSIS BY CANCER TYPE
  219.   6.49 JAPAN MARKET ANALYSIS BY TYPE
  220.   6.50 JAPAN MARKET ANALYSIS BY SOLUTION
  221.   6.51 JAPAN MARKET ANALYSIS BY END-USER
  222.   6.52 JAPAN MARKET ANALYSIS BY CANCER TYPE
  223.   6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE
  224.   6.54 SOUTH KOREA MARKET ANALYSIS BY SOLUTION
  225.   6.55 SOUTH KOREA MARKET ANALYSIS BY END-USER
  226.   6.56 SOUTH KOREA MARKET ANALYSIS BY CANCER TYPE
  227.   6.57 MALAYSIA MARKET ANALYSIS BY TYPE
  228.   6.58 MALAYSIA MARKET ANALYSIS BY SOLUTION
  229.   6.59 MALAYSIA MARKET ANALYSIS BY END-USER
  230.   6.60 MALAYSIA MARKET ANALYSIS BY CANCER TYPE
  231.   6.61 THAILAND MARKET ANALYSIS BY TYPE
  232.   6.62 THAILAND MARKET ANALYSIS BY SOLUTION
  233.   6.63 THAILAND MARKET ANALYSIS BY END-USER
  234.   6.64 THAILAND MARKET ANALYSIS BY CANCER TYPE
  235.   6.65 INDONESIA MARKET ANALYSIS BY TYPE
  236.   6.66 INDONESIA MARKET ANALYSIS BY SOLUTION
  237.   6.67 INDONESIA MARKET ANALYSIS BY END-USER
  238.   6.68 INDONESIA MARKET ANALYSIS BY CANCER TYPE
  239.   6.69 REST OF APAC MARKET ANALYSIS BY TYPE
  240.   6.70 REST OF APAC MARKET ANALYSIS BY SOLUTION
  241.   6.71 REST OF APAC MARKET ANALYSIS BY END-USER
  242.   6.72 REST OF APAC MARKET ANALYSIS BY CANCER TYPE
  243.   6.73 SOUTH AMERICA MARKET ANALYSIS
  244.   6.74 BRAZIL MARKET ANALYSIS BY TYPE
  245.   6.75 BRAZIL MARKET ANALYSIS BY SOLUTION
  246.   6.76 BRAZIL MARKET ANALYSIS BY END-USER
  247.   6.77 BRAZIL MARKET ANALYSIS BY CANCER TYPE
  248.   6.78 MEXICO MARKET ANALYSIS BY TYPE
  249.   6.79 MEXICO MARKET ANALYSIS BY SOLUTION
  250.   6.80 MEXICO MARKET ANALYSIS BY END-USER
  251.   6.81 MEXICO MARKET ANALYSIS BY CANCER TYPE
  252.   6.82 ARGENTINA MARKET ANALYSIS BY TYPE
  253.   6.83 ARGENTINA MARKET ANALYSIS BY SOLUTION
  254.   6.84 ARGENTINA MARKET ANALYSIS BY END-USER
  255.   6.85 ARGENTINA MARKET ANALYSIS BY CANCER TYPE
  256.   6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
  257.   6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY SOLUTION
  258.   6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER
  259.   6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY CANCER TYPE
  260.   6.90 MEA MARKET ANALYSIS
  261.   6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE
  262.   6.92 GCC COUNTRIES MARKET ANALYSIS BY SOLUTION
  263.   6.93 GCC COUNTRIES MARKET ANALYSIS BY END-USER
  264.   6.94 GCC COUNTRIES MARKET ANALYSIS BY CANCER TYPE
  265.   6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE
  266.   6.96 SOUTH AFRICA MARKET ANALYSIS BY SOLUTION
  267.   6.97 SOUTH AFRICA MARKET ANALYSIS BY END-USER
  268.   6.98 SOUTH AFRICA MARKET ANALYSIS BY CANCER TYPE
  269.   6.99 REST OF MEA MARKET ANALYSIS BY TYPE
  270.   6.100 REST OF MEA MARKET ANALYSIS BY SOLUTION
  271.   6.101 REST OF MEA MARKET ANALYSIS BY END-USER
  272.   6.102 REST OF MEA MARKET ANALYSIS BY CANCER TYPE
  273.   6.103 KEY BUYING CRITERIA OF HEALTHCARE
  274.   6.104 RESEARCH PROCESS OF MRFR
  275.   6.105 DRO ANALYSIS OF HEALTHCARE
  276.   6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  277.   6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  278.   6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
  279.   6.109 HEALTHCARE, BY TYPE, 2024 (% SHARE)
  280.   6.110 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion)
  281.   6.111 HEALTHCARE, BY SOLUTION, 2024 (% SHARE)
  282.   6.112 HEALTHCARE, BY SOLUTION, 2024 TO 2035 (USD Billion)
  283.   6.113 HEALTHCARE, BY END-USER, 2024 (% SHARE)
  284.   6.114 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion)
  285.   6.115 HEALTHCARE, BY CANCER TYPE, 2024 (% SHARE)
  286.   6.116 HEALTHCARE, BY CANCER TYPE, 2024 TO 2035 (USD Billion)
  287.   6.117 BENCHMARKING OF MAJOR COMPETITORS
  288. 7 LIST OF TABLES
  289.   7.1 LIST OF ASSUMPTIONS
  290.     7.1.1
  291.   7.2 North America MARKET SIZE ESTIMATES; FORECAST
  292.     7.2.1 BY TYPE, 2025-2035 (USD Billion)
  293.     7.2.2 BY SOLUTION, 2025-2035 (USD Billion)
  294.     7.2.3 BY END-USER, 2025-2035 (USD Billion)
  295.     7.2.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  296.   7.3 US MARKET SIZE ESTIMATES; FORECAST
  297.     7.3.1 BY TYPE, 2025-2035 (USD Billion)
  298.     7.3.2 BY SOLUTION, 2025-2035 (USD Billion)
  299.     7.3.3 BY END-USER, 2025-2035 (USD Billion)
  300.     7.3.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  301.   7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  302.     7.4.1 BY TYPE, 2025-2035 (USD Billion)
  303.     7.4.2 BY SOLUTION, 2025-2035 (USD Billion)
  304.     7.4.3 BY END-USER, 2025-2035 (USD Billion)
  305.     7.4.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  306.   7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  307.     7.5.1 BY TYPE, 2025-2035 (USD Billion)
  308.     7.5.2 BY SOLUTION, 2025-2035 (USD Billion)
  309.     7.5.3 BY END-USER, 2025-2035 (USD Billion)
  310.     7.5.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  311.   7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  312.     7.6.1 BY TYPE, 2025-2035 (USD Billion)
  313.     7.6.2 BY SOLUTION, 2025-2035 (USD Billion)
  314.     7.6.3 BY END-USER, 2025-2035 (USD Billion)
  315.     7.6.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  316.   7.7 UK MARKET SIZE ESTIMATES; FORECAST
  317.     7.7.1 BY TYPE, 2025-2035 (USD Billion)
  318.     7.7.2 BY SOLUTION, 2025-2035 (USD Billion)
  319.     7.7.3 BY END-USER, 2025-2035 (USD Billion)
  320.     7.7.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  321.   7.8 France MARKET SIZE ESTIMATES; FORECAST
  322.     7.8.1 BY TYPE, 2025-2035 (USD Billion)
  323.     7.8.2 BY SOLUTION, 2025-2035 (USD Billion)
  324.     7.8.3 BY END-USER, 2025-2035 (USD Billion)
  325.     7.8.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  326.   7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  327.     7.9.1 BY TYPE, 2025-2035 (USD Billion)
  328.     7.9.2 BY SOLUTION, 2025-2035 (USD Billion)
  329.     7.9.3 BY END-USER, 2025-2035 (USD Billion)
  330.     7.9.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  331.   7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  332.     7.10.1 BY TYPE, 2025-2035 (USD Billion)
  333.     7.10.2 BY SOLUTION, 2025-2035 (USD Billion)
  334.     7.10.3 BY END-USER, 2025-2035 (USD Billion)
  335.     7.10.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  336.   7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  337.     7.11.1 BY TYPE, 2025-2035 (USD Billion)
  338.     7.11.2 BY SOLUTION, 2025-2035 (USD Billion)
  339.     7.11.3 BY END-USER, 2025-2035 (USD Billion)
  340.     7.11.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  341.   7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  342.     7.12.1 BY TYPE, 2025-2035 (USD Billion)
  343.     7.12.2 BY SOLUTION, 2025-2035 (USD Billion)
  344.     7.12.3 BY END-USER, 2025-2035 (USD Billion)
  345.     7.12.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  346.   7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  347.     7.13.1 BY TYPE, 2025-2035 (USD Billion)
  348.     7.13.2 BY SOLUTION, 2025-2035 (USD Billion)
  349.     7.13.3 BY END-USER, 2025-2035 (USD Billion)
  350.     7.13.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  351.   7.14 China MARKET SIZE ESTIMATES; FORECAST
  352.     7.14.1 BY TYPE, 2025-2035 (USD Billion)
  353.     7.14.2 BY SOLUTION, 2025-2035 (USD Billion)
  354.     7.14.3 BY END-USER, 2025-2035 (USD Billion)
  355.     7.14.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  356.   7.15 India MARKET SIZE ESTIMATES; FORECAST
  357.     7.15.1 BY TYPE, 2025-2035 (USD Billion)
  358.     7.15.2 BY SOLUTION, 2025-2035 (USD Billion)
  359.     7.15.3 BY END-USER, 2025-2035 (USD Billion)
  360.     7.15.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  361.   7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  362.     7.16.1 BY TYPE, 2025-2035 (USD Billion)
  363.     7.16.2 BY SOLUTION, 2025-2035 (USD Billion)
  364.     7.16.3 BY END-USER, 2025-2035 (USD Billion)
  365.     7.16.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  366.   7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  367.     7.17.1 BY TYPE, 2025-2035 (USD Billion)
  368.     7.17.2 BY SOLUTION, 2025-2035 (USD Billion)
  369.     7.17.3 BY END-USER, 2025-2035 (USD Billion)
  370.     7.17.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  371.   7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  372.     7.18.1 BY TYPE, 2025-2035 (USD Billion)
  373.     7.18.2 BY SOLUTION, 2025-2035 (USD Billion)
  374.     7.18.3 BY END-USER, 2025-2035 (USD Billion)
  375.     7.18.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  376.   7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  377.     7.19.1 BY TYPE, 2025-2035 (USD Billion)
  378.     7.19.2 BY SOLUTION, 2025-2035 (USD Billion)
  379.     7.19.3 BY END-USER, 2025-2035 (USD Billion)
  380.     7.19.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  381.   7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  382.     7.20.1 BY TYPE, 2025-2035 (USD Billion)
  383.     7.20.2 BY SOLUTION, 2025-2035 (USD Billion)
  384.     7.20.3 BY END-USER, 2025-2035 (USD Billion)
  385.     7.20.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  386.   7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  387.     7.21.1 BY TYPE, 2025-2035 (USD Billion)
  388.     7.21.2 BY SOLUTION, 2025-2035 (USD Billion)
  389.     7.21.3 BY END-USER, 2025-2035 (USD Billion)
  390.     7.21.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  391.   7.22 South America MARKET SIZE ESTIMATES; FORECAST
  392.     7.22.1 BY TYPE, 2025-2035 (USD Billion)
  393.     7.22.2 BY SOLUTION, 2025-2035 (USD Billion)
  394.     7.22.3 BY END-USER, 2025-2035 (USD Billion)
  395.     7.22.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  396.   7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  397.     7.23.1 BY TYPE, 2025-2035 (USD Billion)
  398.     7.23.2 BY SOLUTION, 2025-2035 (USD Billion)
  399.     7.23.3 BY END-USER, 2025-2035 (USD Billion)
  400.     7.23.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  401.   7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  402.     7.24.1 BY TYPE, 2025-2035 (USD Billion)
  403.     7.24.2 BY SOLUTION, 2025-2035 (USD Billion)
  404.     7.24.3 BY END-USER, 2025-2035 (USD Billion)
  405.     7.24.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  406.   7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  407.     7.25.1 BY TYPE, 2025-2035 (USD Billion)
  408.     7.25.2 BY SOLUTION, 2025-2035 (USD Billion)
  409.     7.25.3 BY END-USER, 2025-2035 (USD Billion)
  410.     7.25.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  411.   7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  412.     7.26.1 BY TYPE, 2025-2035 (USD Billion)
  413.     7.26.2 BY SOLUTION, 2025-2035 (USD Billion)
  414.     7.26.3 BY END-USER, 2025-2035 (USD Billion)
  415.     7.26.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  416.   7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  417.     7.27.1 BY TYPE, 2025-2035 (USD Billion)
  418.     7.27.2 BY SOLUTION, 2025-2035 (USD Billion)
  419.     7.27.3 BY END-USER, 2025-2035 (USD Billion)
  420.     7.27.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  421.   7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  422.     7.28.1 BY TYPE, 2025-2035 (USD Billion)
  423.     7.28.2 BY SOLUTION, 2025-2035 (USD Billion)
  424.     7.28.3 BY END-USER, 2025-2035 (USD Billion)
  425.     7.28.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  426.   7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  427.     7.29.1 BY TYPE, 2025-2035 (USD Billion)
  428.     7.29.2 BY SOLUTION, 2025-2035 (USD Billion)
  429.     7.29.3 BY END-USER, 2025-2035 (USD Billion)
  430.     7.29.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  431.   7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  432.     7.30.1 BY TYPE, 2025-2035 (USD Billion)
  433.     7.30.2 BY SOLUTION, 2025-2035 (USD Billion)
  434.     7.30.3 BY END-USER, 2025-2035 (USD Billion)
  435.     7.30.4 BY CANCER TYPE, 2025-2035 (USD Billion)
  436.   7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  437.     7.31.1
  438.   7.32 ACQUISITION/PARTNERSHIP
  439.     7.32.1

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Software
  • Services

Healthcare By Solution (USD Billion, 2025-2035)

  • Clinical Decision Support
  • Drug Discovery and Development
  • Medical Imaging Analysis
  • Personalized Medicine

Healthcare By End-User (USD Billion, 2025-2035)

  • Hospitals and Clinics
  • Research Institutions
  • Pharmaceutical Companies
  • Diagnostic Laboratories

Healthcare By Cancer Type (USD Billion, 2025-2035)

  • Lung Cancer
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Melanoma

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories
Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓